Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer

Roche has decided to scrap its contender taselisib after investigators reported a slight, 2-month progression-free survival advantage for the drug — along with a sketchy safety profile common to the class — combined with fulvestrant hormone therapy in a Phase III study of metastatic breast cancer.